Results 191 to 200 of about 448,470 (384)

Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study

Arthritis &Rheumatology, EarlyView.
Objective This study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk. Methods We conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis.
Achille Marino, Maria Vittoria Cicinelli, Elisabetta Miserocchi, Stefania Costi, Francesco Baldo, Maurizio Virgilio Gattinara, Pierluigi Scandale, Scott D. Smith, Debra A. Goldstein, Dina Baddar, Terese K. A. Gerges, Timothy M. Janetos, Matilde Ruiz‐Cruz, Kazuichi Maruyama, Massimiliano Serafino, Paola Camicione, Vishali Gupta, Radgonde Amer, Emilio M. Dodds, Sebastian Inchauspe, Marion R. Munk, Ester Carreño, Soon‐Phaik Chee, Aniruddha Agarwal, Ariel Schlaen, Ramiro A. Gómez, Cristobal A. Couto, Moncef Khairallah, Piergiorgio Neri, Cecilia B. Chighizola, Roberto F. Caporali, Francesco Pichi   +31 more
wiley   +1 more source

Panamerican Rheumatology

, 1969
M. Mason
openalex   +1 more source

Development of Rheumatology and Rehabilitation Services [PDF]

, 1978
Kenneth L. Tyler
openalex   +1 more source

Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?

Arthritis &Rheumatology, EarlyView.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

Reply

Arthritis &Rheumatology, EarlyView.
Jie Zheng, George Davey Smith, Jonathan H. Tobias   +2 more
wiley   +2 more sources

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. [PDF]

, 2019
ObjectiveLesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was
Baumgartner, Scott, Goldfarb, David S, Jalal, Diana, Pillinger, Michael, Saag, Kenneth G, Schechter, Bruce M, Terkeltaub, Robert, Valiyil, Ritu, White, William B   +8 more
core   +1 more source

What did COVID-19 do to the organization of Italian rheumatology? The examples of Luigi Sacco University Hospital and the Local Health district of ATS Sardegna: the two faces of the same coin [PDF]

Beyond Rheumatology, 2020
Piercarlo Sarzi-Puttini, Donatella Ventura, Marco Antivalle, Alessandra Mutti, Laura Boccassini, Valeria Giorgi, Maria Eva Romano, Giuliana Maria Concetta La Paglia, Anna Manconi, Daniela Marotto   +9 more
doaj   +1 more source

Recent Advances in Rheumatology [PDF]

, 1984
D. G. Palmer
openalex   +1 more source

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis

Arthritis &Rheumatology, EarlyView.
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley   +1 more source

Doctor-patient communication in rheumatology: studies of visual and verbal perception using educational booklets and other graphic material. [PDF]

, 1986
J. M. H. Moll
openalex   +1 more source